Sutro Biopharma

Sutro Biopharma: Focused on developing next generation antibody drug conjugates (ADCs) and multi-specific antibody-based therapeutics for cancer therapy. The company’s discovery and development efforts are driven by its scalable cell-free protein expression platform (Xpress CF) that enables rapid and systematic evaluation of protein structure-activity relationships. Sutro has three wholly-owned ADCs that are on clinical pathways and three high value collaborations with BMS, Merck, and EMD Serono. STRO-001, anti-CD74 ADC, for multiple myeloma and lymphomas is in Phase 1 and showed encouraging initial safety data at EHA & ASH 2019 – additional NHL cohort data will be presented at ASH 2020 and a dose expansion of Ph 1 expected to begin enrolling 1H21. STRO-002 for ovarian and endometrial cancer is also in a Phase 1 trial. At the AACR-NCI-EORTC conference in October 2019, STRO-002 data showed it was well tolerated and demonstrated it’s clinically efficacious at multiple doses (starting at 2.9 mg/kg). Additional Phase 1 data expected during a KOL in 4Q20 and dose-expansion of Ph 1 trial is expected to begin enrolling in 4Q20.
Based in...
US - Pacific
Clinical Stage
Phase l or ll
Disease Space
Autoimmune, Infectious Disease, Oncology
Public, USA
Market Cap
500MM - 1B
Therapeutic Modalities
Antibodies, Platform Technology
310 Utah Ave
Suite 150
South San Francisco, CA 94080
United States

Company Participants at Sutro Biopharma STRO-002 Data Virtual KOL Event 2020

  • Annie Chang
  • Arturo Molina, MD, MS, FACP, Chief Medical Officer
  • Bill Newell, Chief Executive Officer
  • Edward Albini, Chief Financial Officer
  • Trevor Hallam, Ph.D., Chief Scientific Officer

Top 10 Holders of Sutro Biopharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Eventide Asset Management LLC 10.21 2,370,975 47.23 Stakes 12/31/20
BVF Partners LP 5.20 2,368,392 47.18 Stakes 5/22/20
Franklin Advisers, Inc. 9.52 2,211,423 44.05 13F 12/31/20
RA Capital Management LP 9.12 2,118,212 42.19 13F 12/31/20
Vanguard Group, Inc. (Subfiler) 8.02 1,863,040 37.11 13F 12/31/20
BVF, Inc. 7.98 1,854,162 36.93 13F 12/31/20
SV Health Investors LLC 7.86 1,824,542 36.34 13F 12/31/20
The Vanguard Group, Inc. 7.51 1,743,397 34.73 Funds 2/28/21
Baillie Gifford & Co. 7.30 1,695,654 33.78 13F 12/31/20
Samsara Biocapital LLC 7.21 1,675,579 33.38 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.